Clinical Trials Logo

Clinical Trial Summary

This study is designed to examine whether olanzapine (2.5 to 20mg/day) impacts opioid use in patients with opioid use disorder and comorbid SMI symptoms who are taking buprenorphine-naloxone. The specified outcomes (e.g., illicit opioid use, other drug use, sleep, MAT adherence, withdrawal and craving, thought and mood disorder symptoms) on olanzapine will be examined within-subjects for change (improvement) across the trial. Approximately 48 subjects will be enrolled. After enrollment, subjects will complete safety and baseline assessments and will be assigned open-label to 9-weeks olanzapine. Olanzapine will then be tapered over a 1-week period (or maintained if clinically indicated). Urines will be collected 2x/week throughout. The study has 4 distinct phases: 1) Screening (approx. 1-2 wks); 2) Baseline and Medication Initiation Visit (1 visit; includes safety, baseline and phenotyping measures, study medication dispensed) 3) Outpatient treatment (9 wks; 2 visits/wk, includes daily olanzapine and daily buprenorphine-naloxone (through the participants usual community treatment site and on-medication phenotyping measures); 4) Follow-up visit (1 wk after last dose of study medication).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05179772
Study type Interventional
Source University of Pennsylvania
Contact Megan Ivey
Phone 215-746-7712
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date February 2022
Completion date December 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05037682 - Pain and Opioid Management in Older Adults N/A
Completed NCT02559973 - Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder Phase 1
Completed NCT02440256 - Expanded HIV Care in Opioid Substitution Treatment (EHOST) Trial N/A
Completed NCT02593474 - Medication-Assisted Treatment for Youth With Substance Use Disorders Phase 1
Recruiting NCT05180487 - Parenting Young Children Study N/A
Suspended NCT04577144 - An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery-Long Term
Completed NCT03033732 - A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse Phase 4
Recruiting NCT05086835 - A Mobile Executive Functioning Intervention for Momentary Craving in Opioid Use Disorders N/A
Recruiting NCT03821337 - Transcranial Magnetic Stimulation (rTMS) as a Tool to Decrease Pain and Improve Functioning N/A
Recruiting NCT05027919 - Assessing a Clinically-meaningful Opioid Withdrawal Phenotype Phase 2
Recruiting NCT05062577 - A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder Phase 2
Recruiting NCT05143424 - Evaluation of the Interactions of Cannabidiol (CBD) With Morphine Phase 1
Recruiting NCT04375033 - A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder Phase 4
Recruiting NCT04916600 - NET Device for Treating Opioid Use Disorder N/A
Completed NCT02942199 - MySafeRx & MedicaSafe Open-Label Buprenorphine Induction and Lapse Evaluation (MyMOBILE) N/A
Completed NCT02672111 - Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder Phase 3
Completed NCT02044094 - Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder Phase 2
Completed NCT02765867 - Single-dose, Study of RBP-6000 in Opioid Dependent Individuals Phase 1
Completed NCT05127707 - Strategies to Reduce Addiction Stigma Among Health Professionals N/A
Recruiting NCT04567784 - Neuroimaging and CBD for Heroin Use Disorder Phase 2